HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD 4.350
0.00 (0.00%)
Jun 10, 2026, 12:50 PM EST
HLS Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -10.29 | -12.43 | -19.66 | -27.53 | -23.6 | -13.12 |
Depreciation & Amortization | 21.99 | 21.82 | 22.72 | 31.94 | 34.4 | 30.26 |
Stock-Based Compensation | 1.4 | 1.91 | 1.62 | -0.54 | 2.92 | 2.35 |
Other Adjustments | 0.32 | 1.1 | 2.18 | 6.88 | 1.67 | -0.05 |
Change in Receivables | -0.37 | - | - | - | - | - |
Changes in Inventories | 0.65 | - | - | - | - | - |
Changes in Accounts Payable | -0.08 | - | - | - | - | - |
Changes in Income Taxes Payable | 0.07 | - | - | - | - | - |
Changes in Other Operating Activities | 10 | 4.73 | 1.14 | 5.04 | 1.55 | -3.02 |
Operating Cash Flow | 19.95 | 17.13 | 8 | 15.79 | 16.94 | 16.43 |
Operating Cash Flow Growth | 85.31% | 114.05% | -49.31% | -6.81% | 3.12% | 75.82% |
Capital Expenditures | -0.18 | -0.21 | -0.02 | -0.04 | -0.05 | -0.05 |
Purchases of Intangible Assets | -1.88 | -1.5 | - | -0.15 | -0.1 | -0.64 |
Payments for Business Acquisitions | - | - | -1.5 | - | -10 | -3.82 |
Proceeds from Business Divestments | - | - | 13.25 | - | - | - |
Investing Cash Flow | -2.07 | -1.7 | 11.74 | -0.19 | -10.15 | -4.51 |
Long-Term Debt Issued | 57.24 | 57.24 | - | - | 10 | - |
Long-Term Debt Repaid | 49.97 | 74.99 | 21.04 | 8.86 | 9.78 | 10.5 |
Net Long-Term Debt Issued (Repaid) | 107.21 | 132.23 | 21.04 | 8.86 | 19.78 | 10.5 |
Issuance of Common Stock | - | - | - | 0.13 | 0.18 | 4.91 |
Repurchase of Common Stock | 1.62 | 1.8 | 0.6 | 1.55 | 1 | 0.05 |
Net Common Stock Issued (Repurchased) | 1.62 | 1.8 | 0.6 | 1.69 | 1.18 | 4.96 |
Common Dividends Paid | - | - | - | -2.4 | -4.96 | -5.12 |
Other Financing Activities | -2.02 | -2 | -1.72 | -1.97 | -1.3 | -0.64 |
Financing Cash Flow | -23.54 | -21.56 | -23.36 | -14.64 | -6.86 | -11.4 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.24 | 0.4 | -0.87 | 0.27 | -0.39 | 0.05 |
Net Cash Flow | -5.41 | -5.73 | -4.5 | 0.96 | -0.06 | 0.52 |
Free Cash Flow | 19.77 | 16.93 | 7.99 | 15.75 | 16.9 | 16.38 |
Free Cash Flow Growth | 16.81% | 111.88% | -49.28% | -6.80% | 3.14% | 76.00% |
FCF Margin | 35.47% | 30.50% | 14.11% | 24.97% | 27.49% | 27.30% |
Free Cash Flow Per Share | 0.63 | 0.54 | 0.25 | 0.49 | 0.52 | 0.51 |
Levered Free Cash Flow | 129.36 | 146.14 | 25.23 | 18.26 | 32.08 | 24.58 |
Unlevered Free Cash Flow | 27.35 | 21.05 | 17.17 | 20.53 | 17.32 | 20.03 |